The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive biliary tract
The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive biliary tract
האישור ניתן ל-zanidatamab-hrii, הידוע גם כ-Ziihera, נוגדן דו-ספציפי המכוון ל-HER2. הוא מיועד לחולים עם סרטן דרכי המרה חיובי ל-HER2 שאינו ניתן לכריתה (לא ניתן להסרה בניתוח) או גרורתי (התפשט לחלקים
In a report released today, Peter Welford from Jefferies maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF270.00. The company’s shares
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, companion diagnostic test to be made widely available
In a report released today, Matthew Weston from UBS maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF270.00. The company’s shares